We further examined their in vitro anti-AD activities involving multiple drug targets containing Aβ42, BACE1, glycogen synthase kinase 3β (GSK-3β), AChE, as well as neuroinflammation and oxidative damage. Here, BACE1 is linked to Alzheimer disease.